Kartesia exits stake in ADL Biopharma

• ADL will be integrated into Wacker Biosolutions
• Kartesia invested in ADL in 2019 and became sole shareholder in 2021
• Kartesia is a pan-European firm financing small and middle-market companies

Kartesia has sold ADL Biopharma, a Spanish bioingredients company, to Wacker Chemie AG, a multinational chemical group. No financial details of the transaction were disclosed.

ADL is headquartered in Leon, Spain. The firm is a European CDMO in the field of precision fermentation, providing scale-up and manufacturing services for a number of end-markets.

ADL will be integrated into Wacker Biosolutions, the biotechnology division of Wacker Chemie.

Kartesia first invested in ADL in 2019 and became sole shareholder in 2021.

ADL has more than doubled revenues under Kartesia’s ownership.

“It has been a pleasure to work with Ignacio and his team as ADL has grown in topline, profitability, and human capital since we came on board in 2021,” said Tomas Neuhaus, investment director at Kartesia.

Kartesia’s investment was structured from the Kartesia Credit Opportunities IV (KCO IV) fund.

Kartesia, headquartered in London, is a pan-European firm financing small and middle-market companies. The firm manages over €4 billion in assets. It has offices in Brussels, Frankfurt, London, Luxembourg, Madrid, Munich, and Paris.

Wacker Biosolutions offers services and products for the life-science sector, including pharmaceutical proteins, cyclodextrins and fermentation-generated L-cysteine. It is the Munich-based Wacker Group’s life-sciences division.